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AbstrACt 
background and aim There is growing interest in the use 
of medication-assisted treatments for gambling disorder 
(GD). Opioid receptor antagonists are hypothesised to blunt 
the craving associated with gambling. This study was 
designed to assess the feasibility of using an intranasal 
naloxone spray to treat GD.
Design An 8-week, open-label, uncontrolled pilot study.
setting A single study site in the capital region of Finland.
subjects Twenty problem gamblers (nine men) were 
randomised into two groups. Group A (n=10) took one 
dose into one nostril (2 mg naloxone), as needed, with a 
maximum of 4 doses/day (max. 8 mg/day). Group B (n=10) 
took one dose into each nostril (4 mg naloxone) as needed, 
with a maximum of 4 doses/day (max. 16 mg/day).
Intervention Naloxone hydrochloride nasal spray.
Measures Acceptability and feasibility of the intervention 
were assessed. Use of study medication, adverse events, 
gambling frequency and gambling expenditure were 
recorded in a mobile diary. Problem gambling: South Oaks 
Gambling Screen (SOGS), depressive symptoms: Beck 
Depression Inventory (BDI) and alcohol use: Alcohol Use 
Disorders Identification Test were recorded.
results Study completion rate was 90%. Acceptability 
and feasibility scores were high. Group B used intranasal 
naloxone more frequently than group A, and consequently 
used more naloxone. No serious adverse events were 
reported. The postintervention SOGS scores were lower 
(median=4 (IQR=3.75) versus preintervention scores 
(median=12 (IQR=4.75)). Depressive symptoms were 
reduced during the trial (preintervention BDI median=9, 
IQR=9 vs postintervention BDI median=6, IQR=6).
Conclusions The acceptability and feasibility of using 
intranasal naloxone were high, and no serious adverse 
events were reported. Preliminary results suggest mixed 
results in terms of gambling behaviour (ie, reduced 
frequency but not expenditure) and decreased depressive 
symptoms.
trial registration number EudraCT2016-001828-56 
IntroDuCtIon
Gambling disorder (GD) is a behavioural 
addiction that shares neurobiological and 
clinical similarities with substance use 
disorders.1 2 Typical clinical presentations of GD 
include tolerance, withdrawal symptoms and 
craving.1 These presentations cause many types 
of harm and significant impairment of an indi-
vidual’s psychological, social and professional 
functioning.3 Despite these harms, treatment 
seeking is relatively rare.4 The reasons for infre-
quent treatment seeking include fear of stigma, 
lack of efficacious treatments, and limited avail-
ability and access to treatments.5 Low adher-
ence to therapy is also common.6 Therefore, 
efficacious, easily used and acceptable (patient-
friendly) treatments that can be implemented 
in real-life clinical practice are needed.
The biological, psychological, social and 
cultural background factors underlying GD 
are largely similar to those of other addictive 
conditions.7 To date, psychopharmacolog-
ical interventions have shown only modest 
benefits in treating GD. The strongest empir-
ical support exists for the use of mu-opioid 
receptor (MOR) antagonists such as 
naltrexone and nalmefene,8 although the find-
ings are mixed. Thus, in placebo-controlled 
strengths and limitations of this study
 ► Key strength of the study is a novel treatment ap-
proach, as-needed intranasal naloxone spray to 
treat gambling disorder.
 ► Pilot study forms the basis for an randomised con-
trolled trial (RCT).
 ► Main limitation of this study was lack of a placebo 
arm.
 ► The ‘modified’ South Oaks Gambling Screen ver-
sion (gambling in last 12 months (screening) or last 
2 months (end)) has not been validated for measur-
ing changes in gambling behaviour.
 ► Another limitation was the small number of partici-
pants; only 11 participants were treatment seekers, 
9 participants enrolled after reading a newspaper 
advertisement about the study.
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studies, treatment outcomes with these opioid antago-
nists have been disappointing, with no statistically signif-
icant differences found between treatment arms in the 
severity of gambling, despite some positive medication 
effects.9 Psychotherapeutic and behavioural treatment 
approaches can also result in significant improvements in 
GD patients, as shown with even brief interventions such 
as a 15 min telephone consultation.10 11
To date, two different MOR antagonist drugs (naltrexone 
and nalmefene) have been investigated in the treatment 
of GD.12–16 Orally administered naltrexone and nalmefene 
share possible common drawbacks that may contribute to 
their modest effects on gambling behaviour. These include 
low medication adherence and a relatively long duration of 
action that could impact activities which require endogenous 
opioidergic tone. There are potential advantages offered by 
transient MOR antagonism, that is, an ‘as-needed’ reduc-
tion in MOR availability, with the potential for maintaining 
physiological reward functions when addiction cues are not 
present. For as needed applications, intranasal administra-
tion of a spray formulation of naloxone exhibits rapid entry 
of the drug into the systemic circulation, combined with a 
short elimination half-life in plasma (~2 hours17–19) relative 
to other opioid antagonists. The intranasal formulation used 
in the present study is identical to the one described in,19 
yielding pharmacologically relevant plasma levels as rapidly 
as an intramuscular injection.
The safety and rapid onset of action of intranasal 
naloxone, leading to its approval to treat opioid over-
dose, is supported by several previous clinical trials,19 20 
and a recent PET imaging study has shown that intranasal 
naloxone produces high MOR occupancy in the central 
nervous system within minutes.21
We hypothesised that the use of ‘as needed’ (see 
Methods and materials section) intranasal naloxone 
combined with brief telephone consultations might 
lower the threshold for treatment seeking and could 
be readily implemented in a variety of clinical settings. 
Prior to launching a placebo-controlled proof-of-con-
cept study to test this hypothesis, we designed and 
conducted a feasibility study in order to answer the 
question: ‘Can this study be done?’.22 Feasibility studies 
are used to estimate important parameters that are 
needed to design a proof-of-concept study, especially 
when testing a new type of intervention.23–25 Thus, the 
goal of this study was to evaluate the acceptability, feasi-
bility and outcomes of conducting an 8-week treatment 
trial using as needed naloxone combined with tele-
phone contacts in GD patients with respect to subject 




Study participants were recruited by newspaper and online 
advertisements. Online advertisements were sent to organi-
sations that offer treatment or support services to gamblers 
seeking help, including Helsinki Gambling Clinic, A-Clinic 
Foundation (offers treatments for addictions), Peluuri 
(national gambling helpline) and newspaper advertise-
ments were published in the Helsinki region. These adver-
tisements described the trial’s aim to provide support and 
treatment for GD. The sample size was based on previously 
reported.26 27 feasibility/pilot studies with similar objec-
tives, a sample size of 20 was considered adequate. A total 
of 30 individuals contacted the research coordinator per 
phone or email after completing a self-administered online 
screen (South Oaks Gambling Screen, SOGS, ‘modified’ to 
capture behaviours over the last 12 months).28–30 Scoring 
of the SOGS screen was as follows: (1) 0=no problem 
with gambling, 1–4 some problems with gambling, 5 or 
more=probable pathological gambler (see modified SOGS 
last 12 months online supplement S1). Of these, 10 persons 
were excluded and 20 subjects were enrolled in the study. Of 
the 20 individuals enrolled in the study, 11 were recruited 
via treatment or treatment seeking services, and 9 found 
the study information via newspaper advertisements.
Inclusion criteria
The inclusion criteria were last-year gambling problem at 
prescreening (SOGS ≥5), age >18 years, able to provide 
written informed consent, criteria met for GD (Diagnostic 
and Statistical Manual of Mental Disorders, 5th editon 
(DSM-5))1 as assessed by clinician interview, fluency in 
the Finnish language and willingness to fill the mobile 
gambling and AEs diary, and willingness to comply with 
other procedures and visits.
exclusion criteria
The exclusion criteria were <8 weeks since any previous 
treatment with naltrexone, nalmefene or naloxone; 
current use of opioids or illicit drugs, as assessed by 
saliva drug screen; any intranasal medication; active 
HIV or Hepatitis C virus (HCV) infection; hepatic or 
renal impairment; serious mental illness as assessed by 
clinical interview (DSM-5), severe depression (Beck’s 
Depression Inventory, BDI score >24)31; women of 
childbearing potential unless using effective contracep-
tion; pregnant or breastfeeding women; persons inca-
pable of providing valid informed consent according to 
Finnish Medical Research Act # 188/1999 (eg, being a 
prisoner, mental retardation).
The study was conducted between the 14 February and 
the 30 May, 2017, at a single study site at the National Insti-
tute for Health and Welfare in Helsinki, Finland, in accor-
dance with the Declaration of Helsinki and Good Clinical 
Practice. All subjects gave written informed consent. The 
study protocol, the informed consent form and other 
study-related materials were reviewed and approved by 
the Finnish Medicines Agency Fimea (number: Klnro 
128/2016) and the National Ethics Committee (number: 
152/06.00.01/2016).
Procedures
Intranasal naxolone and drug administration
The study medication was a nasal multispray formulation 
of naloxone hydrochloride (20 mg/mL nasal spray). One 
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dose delivers 0.1 mL of the formulation (2 mg) into one 
nostril. The manufacturer was Sharp Clinical Service (UK) 
Limited, Crickhowell, UK. The investigational medicinal 
product was donated by Opiant Pharmaceuticals, Santa 
Monica, CA, USA, without terms or conditions. The subjects 
were instructed to administer the study medication in an 
as-needed manner when experiencing an urge to gamble 
or in a situation where the individual felt that relapse was 
imminent.
The subjects (n=20) were allocated (in an alternating 
sequence) by the study physician 1:1 into two groups: 
subjects in group A were instructed to take one dose into 
one nostril (2 mg naloxone), up to four times per day 
(max. 8 mg/day) with at least 2 hours between each dose. 
Subjects in group B were instructed to take one dose into 
both nostrils (4 mg naloxone), up to four times per day 
(max. 16 mg/day) with at least 2 hours between each dose. 
Both 2 and 4 mg dose strengths of naloxone nasal spray are 
commercially available, and these doses were thus selected 
for this study. However, using a single concentration of 
naloxone and instructing the subjects to dose into one 
(group A) or both (group B) nostrils was deemed a simpler 
approach from an operational standpoint. Naloxone is safe 
and well-tolerated intranasally and the maximum adminis-
tered daily dose (16 mg intranasal (IN)) falls well below the 
total exposure achieved by intravenous doses that can be 
used to rescue overdose victims.32 Use of study medication, 
AEs, gambling frequency and gambling expenditure were 
recorded on a daily basis into a mobile diary.
Study participation required three visits to the clinic 
and two telephone contacts (see study flow, figure 1). The 
brief supportive phone calls followed the framework of the 
BRENDA (a psychosocial program integrating psychoso-
cial treatment and pharmacotherapy) model33 (all visits 
described online supplement S2).
Visits
Screening visit
At a screening visit (week 0) conducted by a research coordi-
nator, the following information was collected after signing 
the informed consent: preliminary check of inclusion and 
exclusion criteria; problem-level gambling assessed by 
SOGS (over the last 12 months)28–30; alcohol consumption 
assessed with the Alcohol Use Disorders Identification Test 
(AUDIT-C)34–36; smoking habits (yes/no); depressive symp-
toms assessed with the BDI,30 background information (age, 
gender, other medical conditions and medication) and 
sociodemographic information (education, marital status, 
employment status, housing conditions). Blood and urine 
samples were collected for basic haematology and biochem-
istry tests and to exclude HIV and HCV infection, opioid 
use and pregnancy. All laboratory tests were conducted in a 
certified laboratory in Helsinki.
baseline visit (week 0)
At a baseline visit (week 0), eligible subjects were assigned 
to 8-week treatment with as-needed self-administration of 
nasal naloxone spray as described above.
First, the study physician confirmed the inclusion/
exclusion criteria, assessed medical conditions and issues 
including other medications being taken, and performed 
a visual examination of the nasal mucosa using a nasal 
irritation score on a scale of 0–5. The definitions of 
each point of the scale are provided below: 0=normal 
appearing mucosa, no bleeding; 1=inflamed mucosa, no 
bleeding; 2=minor bleeding which stops within 1 min; 
3=minor bleeding, taking 1–5 min to stop; 4=substantial 
bleeding for 4–60 min, does not require medical inter-
vention; 5=ulcerated lesions, bleeding which requires 
medical intervention. The study physician also checked 
the laboratory results that were sent from the laboratory, 
Figure 1 Participant flow (CONSORT diagram). CONSORT, Consolidated Standards of Reporting Trials. 
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and screened and evaluated the subject’s risk of suicide 
using a three-item questionnaire.36 None of these data 
were analysed. Subjects meeting the inclusion and exclu-
sion criteria were randomised on a 1:1 basis into the two 
treatment groups. Subjects were provided with a supply 
of study medication for the study duration and appro-
priate information about the study medicine. In addition, 
all subjects were given a copy of the self-help manual 
‘Becoming a Winner’.37 38
Subjects were presented a questionnaire assessing their 
perceptions of the appropriateness for addressing the 
problem, convenience, effectiveness, risks and adherence 
(acceptability) and applicability, practicality of applying 
the treatment, and clarity of the treatment protocol 
(feasibility) of intranasal medication (see online supple-
ment S3 for translated questionnaire). This questionnaire 
consisted of 14 questions with 9-point Likert rating scales 
(1=not at all to 9=extremely). Items were created based 
on categories for testing acceptability (seven items) and 
feasibility (seven items).25 A three-item questionnaire was 
used to assess motivation for change (importance, readi-
ness and certainty) using an 11-point Likert scale (0=not 
at all to 10=extremely) (see feasibility questionnaire in 
online supplement S3).
Subjects were trained by the study nurse on the use of a 
daily mobile questionnaire, and self-administration of the 
study medication was instructed by the study physician. 
Text message questions were (1) How many times did you 
take medication yesterday, with the answering options 
of zero to four times per day; (2) Did you experience 
any AEs during the day? The subjects were instructed to 
record any unusual event in the diary, such as headache, 
back pain, influenza, nausea, gastrointestinal pain, sports 
injury and so on. All AEs were rated by the study physician 
as follows: (1) severity; three-point Likert-scale (1=mild, 
2=moderate, 3=severe); (2) relationship to study medica-
tion was rated five-point Likert-scale (1=definitely related 
to 5=not related). Adverse drug reactions and unex-
pected adverse drug reactions and serious adverse events 
(SAEs) were to be recorded and reported, but none were 
observed. Other text message questions were (3) Did you 
gamble yesterday (yes/no); (4) How much money did you 
spend on gambling (euros); (5) How much time did you 
spend on gambling (hours and minutes). Subjects were 
instructed to reply to the text message reminders daily. 
The next contact (week 2 phone call) was scheduled.
Week 2 and week 5 contacts
In weeks 2 and 5, a feasibility assessment of the naloxone 
nasal spray and an evaluation of the treatment protocol 
was performed with phone calls by the research coordi-
nator. Questions during the calls were focused on the 
usability of the study medication (including possible 
technical issues with the nasal spray device), use of other 
medications, AEs, usability of the mobile diary (including 
technical problems sending or receiving text messages) 
and a brief supportive conversation about problem 
gambling using the contents of the self-help manual as a 
guideline. At the end of the week 5 contact, a clinic visit to 
meet the study physician was scheduled for 3 weeks later 
(study week 8).
Week 8 visit
At this end-of-study visit, a 14-item questionnaire was 
presented in order to evaluate the acceptability and feasi-
bility of the as needed medication and nine questions 
were asked about the participant’s experiences during the 
treatment. The SOGS (related to gambling behaviours 
during the trial (see online supplement S4), modified 
SOGS last 2 months), AUDIT-C and BDI questionnaires 
were administered. In addition, an examination of the 
nasal mucosa was conducted. Further treatment referrals 
were made for those who requested it. One open-ended 
question was also presented: ‘In your opinion, what 
Table 1 Pretreatment demographics of all participants and the two treatment groups (median, first and third quartiles for 







Male % 44 38 50
Female % 56 62 50
Age (years), median;
(first and third quartile)
47.00; (40.25, 55.50) 47.00; (37.25, 51.00) 48.00; (41.00, 56.75)
SOGS, median;
(first and third quartiles)
12.00; (10.00, 13.75) 12.00; (10.75, 14.25) 11.50; (10.0, 13.0)
BDI, median;
(first and third quartiles)
9.00; (4.5, 13.75) 14.50; (12.75, 16.00) 5.00; (3.00, 7.00)
AUDIT-C, median;
(first and third quartiles)
4.00; (2.25, 5.00) 4.00; (2.00, 4.25) 4.00; (3.00, 5.75)
n, 18; t-test, male/female p value; Wilcoxon’s test: age, SOGS (last 12 months) (score: ≥5, probable pathological gambler), BDI (score: 
1–9=no depression; 10–18=mild depression; 19–29=moderate depression; 30–63=severe depression) and AUDIT-C (score=4 women indicates 
hazardous drinking and score 5=men indicates hazardous drinking, maximum score 12).
AUDIT, Alcohol Use Disorders Identification Test; BDI, Beck Depression Inventory; SOGS, South Oaks Gambling Screen. 
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are the pros/cons of using a nasal spray medication in 
treating problem gambling?’
Data analyses
Data were analysed using R Studio and R V.3.4.1.39 Descrip-
tive statistics were used to provide summaries about the 
sample and the measurements. The effect size was esti-
mated using Cliff’s delta-within statistic for paired data, 
which is the difference between the proportion of individual 
subjects who change in one direction and the proportion of 
individuals who change in the other direction. The effect 
size values are negative to show the direction of the desired 
changes in the SOGS, AUDIT and BDI scores. Regres-
sion analysis were used to handle and further estimate the 
missing values when analysing a gambling diary data, specif-
ically expenditure or time gambled.
results
recruitment
Of those 30 persons who contacted the research coor-
dinator, 10 persons either refused participation or were 
excluded from participating in the study. Recruitment 
was completed when all 20 participants were enrolled. 
Reasons for refusal are listed in figure 1.
Twenty subjects were enrolled in the study and 18 
persons completed the study; both drop outs occurred 
at week 5 (both for personal reasons and both in group 
A). Eighteen subjects were thus included in the outcome 
analysis (8 in group A and 10 in group B).
Descriptors
Eleven of the 20 subjects were female. The average age 
was 44 years (n=18) (median=47, range 18–74, Q1=40.25, 
Q3=55.50, IQR=15.25). Eleven of the subjects were 
married or cohabited, 9 had only a primary school educa-
tion and 14 were working.
At baseline, the last 12 months SOGS scores of the 
subjects had a median of 12 (range 8–19, IQR=3.75). BDI 
scores had a median of 9 (range 1–19, IQR=9.25), and 
alcohol consumption as assessed with AUDIT-C was on 
a moderate level (median=4, range 0–9, IQR=2.75) (see 
table 1). Two-thirds of the subjects were smokers.
Table 1 here on a scale from 0 to 10, the subjects 
perceived their attitudes towards changing their 
gambling behaviour as follows: importance (median=10, 
range 6–10, Q1=9.75, Q3=10.00, IQR=0.25), certainty 
(median=5, range 0–10, Q1=4.00, Q3=8.00, IQR=4) and 
readiness (median=9, range 2–10, Q1=5.00, Q3=10.00, 
IQR=5.00).
Acceptability and feasibility of using the naloxone nasal spray
At baseline, the subjects had high perceptions of the 
acceptability of using nasal spray to treat GD (median=9, 
range 3–9, Q1=9, Q3=9), and acceptability remained 
high also post-treatment (median=9, range 1–9, Q1=9, 
Q3=9). The subjects’ high perception of the feasibility 
of the approach did not change from preintervention 
(median=9, Q1=9, Q3=9) to postintervention (median=9, 
Q1=9, Q3=9).
experiences from the treatment
Open-ended questions regarding their experience and 
opinions of the study. Sixteen of the 18 subjects reported 
that they would be willing to participate in a similar study 
in the future. The quotes of the subjects’ are in online 
supplement S5.
Table 2 Group A and group B with 4 mg dose of medicine: number of gambling occasions when probability, minutes and 
euros spent in gambling after taking medicine
Group/medicine 
dose
No of gambling 
occasions when 
subjects took 
medicine and were 
gambling
No of gambling 
occasions when 
subjects took 










spent on gambling 




15 18 0.45 150 129€
Group B
(1×4 mg)
14 92 0.13 123 55€
Dose, no of gambling occasions when medicine was taken and subject gambled, no of gambling occasions when medicine was taken and 
subject did not gamble, of gambling after taking medicine, minutes (mean) gambled if gambled after taking medicine, euros spent in gambling 
(mean) if gambled after taking medicine, that were recorded in the daily diary were analysed. n, 18.
Table 3 Adverse events for both treatment groups coded 













All AEs 19 9
n, 18; study medication-related adverse events coded by study 
physician either related or not related to the study medication.
AEs, adverse events.
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evaluation of the feasibility of research methods
Of the 20 enrolled subjects, 18 (90%) completed the 
8-week treatment. Drop out cases were treated as missing 
data when describing the SOGS, BDI and AUDIT-C 
scores at study start and end. Any AEs of the discontinued 
subjects were incorporated into the AE database.
On 73% of those days when the study medication was 
used, no gambling was recorded. The dose that was most 
used was 4 mg/day regardless of study group. Further, 
when the daily dose of 4 mg was specifically explored 
(in group A: 2×2 mg; in group B: 1×4 mg), reductions in 
gambling were observed (took medicine and gambled 
vs did not gamble) in group B (1×4 mg dose) compared 
with group A (2×2 mg). Probability of gambling when 
taking medicine in group A (2×2 mg dose) was 0.45 and 
the probability of gambling when taking medicine in 
group B (1×4 mg) was 0.13 (table 2). When one partic-
ipant who discontinued filling the diary and one drop 
out were removed from the analyses, there were 8 days 
which are non-completed, in other words on only 0.8% 
of all study days there were no diary entries (n=18). 
There were instances where the participant did not 
remember the duration of the gambling time or money 
spent, this was resolved using regression analysis.
Adverse events
Subjects in group A reported more AEs (19 events) 
than those in group B (9 events). The group difference 
in AEs not related to study medication (group A, n=15; 
group B, n=3) was deemed large for a study of this size, 
but the AEs related to study medication were similar 
(group A, n=4, group B, n=6) (table 3). The medica-
tion ‘related’ AEs in group A were headache, nausea, 
itchy nose, stuffy nose and runny nose, while subjects in 
group B reported fatigue, dizziness and loss of appetite.
Changes in gambling behaviour, depressive symptoms and 
alcohol use
At the conclusion of the 8-week trial, a reduction in 
gambling severity was observed (figure 2). SOGS scores 
were markedly reduced from baseline values (n=18) 
(median=12, range 8–19, Q1=10.00, Q3=13.75, IQR=3.75) 
in the repeat scoring carried out at the end of the treat-
ment period (median=4, range 0–10,Q1=1.25, Q3=6.00, 
(IQR=4.75; effect size=−0.8888, 95% CI (−0.4251 to 
−0.9830)), indicating a decline in gambling behaviour 
(table 4). Descriptives of gambling behaviour time 
(minutes) and money spent in gambling, doses of medi-
cation, times gambled per week, mean scores and first 
and third quartile of euros and time from the gambling 
diary are reported in table 5 showing fluctuation in all 
variables.
Figure 2 Problem gambling severity measured by South 
Oaks Gambling Screen (SOGS) before and after the trial 
(both groups). N=18; SOGS scores were used with the 
following timeframes; pretreatment (last 12 months) and 
post-treatment (last 2 months). SOGS score ≥5 refers to a 
probable pathological gambler. The bottom and top lines are 
minimum and maximum values. The box includes all values 
between Q1 and Q3. Bolded line inside the box is the median 
(Q2) value. 
Table 4 Median, mean, range, IQR, first and third quartiles and effect size and CIs of gambling severity, depressive symptoms 
and alcohol risk consumption at baseline and after the trial
Median Mean Range
IQR; (first and third 
quartiles) Effect size (95% CI)
SOGS Baseline 12.00 12.11 8–19 3.75; (10.00; 13.75) −0.8888 (−0.425 to −0.9830)
Post-treatment 4.00 3.94 0–10 4.75; (1.25; 6.00)
BDI Baseline 9.00 9.39 1–19 9.25; (4.5; 13.75) −0.7778 (−0.3757 to −0.9334)
Post-treatment 5.50 5.67 0–12 5.50; (2.25; 7,75)
AUDIT C Baseline 4.00 3.89 0–9 2.75; (2.25; 5.00) 0 (0.3229 to −0.3229)
Post-treatment 4.00 3.83 0–9 3.00; (2.00; 5.00)
n, 18; SOGS (last 12 months vs last 2 months) (score: ≥5, probable pathological gambler), BDI (score: 1–9=no depression; 10–
18=mild depression; 19–29=moderate depression; 30–63=severe depression) and AUDIT-C (score=4 women indicates hazardous drinking and 
score 5=men indicates hazardous drinking, maximum score 12).
AUDIT, Alcohol Use Disorders Identification Test; BDI, Beck Depression Inventory; SOGS, South Oaks Gambling Screen. 
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BDI scores were also lower at study end (n=18) 
(median=5.50, range 0–12, Q1=2.25, Q3=7.75, IQR=5.50) 
compared with baseline (median=9, range 1–19, Q1=4.50, 
Q3=13.75, IQR=9.25; effect size=−0.7778, 95% CI (−0.3757 
to −0.9334)). BDI scores improved for 15 subjects, 
remained the same for two subjects, and increased for 
one subject. Self-reported alcohol consumption was not 
changed during the trial (table 4).
DIsCussIon
To our knowledge, this is the first report of the use of a 
nasal naloxone spray, administered on an as needed basis, 
to treat GD. The primary objective of this open-label study 
was to assess the safety, acceptability and feasibility of use, 
and outcomes of naloxone nasal spray in the treatment of 
treatment of GD by combining naloxone nasal spray with 
brief supportive phone calls.
Acceptability and feasibility of the intervention
Overall, the subjects’ attitudes towards using as-needed 
naloxone nasal spray were positive, which indicates good 
acceptance and feasibility of the treatment. A low drop 
out rate (10%) also suggests good adherence to the treat-
ment, much higher than in most previous treatment 
studies.14 15 At study start, the subjects’ overall rating of 
importance for changing their gambling behaviour was 
high. High acceptance and feasibility ratings combined 
with high readiness for change may have contributed to 
the good outcome of this trial.40 Answers to the open-
ended question also indicated that the subjects perceived 
the nasal spray medication easy to use and acceptable. 
However, this sample may not be an accurate reflection 
of populations currently seeking treatment for gambling 
issues/problems, since nearly half of the study partici-
pants were recruited via newspaper advertisements.
Feasibility of the research methods
The recruitment process was managed within a similar 
time frame as in previous studies,15 41 using online sources 
and local newspaper advertisements. The sample demo-
graphics are in line with other corresponding studies.14 15
The SOGS (last 12 months) was used as a prescreening 
instrument, and all potential subjects prescreened with 
SOGS subsequently fulfilled the diagnostic criteria in the 
study physician’s clinical interview. This implies that the 
online SOGS prescreen can also be used in a larger, place-
bo-controlled proof-of-principle study.
Based on diary data, adherence to study medication 
was acceptable and the study protocol was implemented 
as planned. Phone calls were conducted by a trained 
Table 5 Descriptives of weekly euros and time (in minutes) spent in gambling and milligrams of study medicine taken, 
occasions gambled in a week presented in group sum; mean scores (€ and time spent in minutes per week) and first and third 













  1 1204 1770 98 14 86 8.0; 100.0 126 30.0; 240.0
  2 1080 1350 76 10 108 40.0; 200.0 135 120.0; 180.0
  3 340 330 52 4 85 27.5; 125 82.5 17.5; 135.0
  4 945 1000 62 8 118 25.0; 210.0 122 52.5; 135.0
  5 351 860 52 6 58 25.0; 70.0 143 120; 180.0
  6 217 420 26 5 43 5.0; 100.0 84 20.0; 180.0
  7 750 660 16 4 188 137.5; 225.0 165 52.5; 180.0
  8 1445 1210 34 7 206 55.0; 325.0 173 75.0; 225.0
Group B
  1 1212 2010 244 12 101 18.8; 82.5 168 10.0; 80.0
  2 368 975 272 11 33 11.0; 40.0 89 15.0; 60.0
  3 983 955 164 7 140 26.0; 57.5 136 70.0; 210.0
  4 584 496 164 8 73 40.0; 97.5 62 30.0; 67.5
  5 510 1155 188 7 73 50.0; 110.0 165 32.5; 240.0
  6 618 792 108 9 69 38.0; 68.0 88 24.0; 60.0
  7 294 374 108 6 49 21.5; 66.0 62 25.5; 60.0
  8 902 693 56 12 75 16.5; 100.0 58 17.5; 90.0
N=18. Missing values: if gambled but both euros and time missing, estimated with mean values of the person. If euros OR time missing, the 
missing value was estimate with regression analysis.
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research coordinator, who followed the script consistently 
with each subject—keeping a log that was checked after 
the study, indicating very good intervention fidelity. Both 
treatment duration and frequency of appointments were 
perceived positively by the study subjects. This study used 
telephone messages to remind the subjects to fill in the 
daily gambling diary. The naloxone nasal spray device 
functioned well; one subject reported that the spray bottle 
had broken, and two subjects reported that the spray did 
not come out evenly, but they were provided with backup 
devices that worked well.
The reported AEs were classified by the study physician. 
There were more reported AEs in the lower dose group 
(group A). Study medication-related AEs were nausea, 
headache or loss of appetite, and GI pain, commonly 
reported with opioid antagonist medications.19 As 
presented in table 3, the frequency of related AEs was 
not dose dependent. Addition of a placebo arm will be 
necessary to better understand the relationships between 
naloxone dose, dosing frequency and AEs. However, 
no SAEs were detected/reported.
An analysis between of study medicine dose (ie, group 
A vs group B) and gambling expenditure and time did 
not indicate dose dependence. There was considerable 
variation in the frequency of dosing among the partici-
pants. Of the 18 subjects completing the trial, only 4 
individuals took the maximum permissible dose (4×/
day) with varying frequency, ranging from 1 to 14 days 
out of a total of 60 possible days (8 weeks’ trial duration). 
The maximum dosage (4x/day) was taken 18 times: 1 
subject did this 14 times and the remaining three subjects 
took the maximum dosage on 1 or 2 days. Participants 
used study medication on 34% of all days during their 
participation. However, in view of the small sample size, 
rendering the outcome sensitive to confounding factors 
such as the severity of addiction, larger-scale studies 
including a placebo control arm will be required to deter-
mine a minimum effective dose.
The use of study medication was associated with a reduc-
tion in gambling in 73% of the subjects, as assessed using 
diary data. Reduction in gambling severity measured with 
a modified version of SOGS was also observed, but with no 
apparent differences related to total dose (see figure 2). 
While the SOGS measure showed a decline in gambling 
behaviour from pretreatment to post-treatment, it has 
only been validated as a tool for assessing severity of 
gambling, with questions framed with the wording: ‘Have 
you ever…’.42 Thus, in the context of the present study, 
these observed reductions can only be seen as sugges-
tive, since this particular measure has two limitations: 
the timeframes pretreatment and post-treatment are very 
different and thus not comparable, and the SOGS does 
not measure reduction in urges, yet in this sample the 
scores reflect reductions in gambling behaviour. Other 
limitations of our study include lack of a placebo control, 
a small study size and the use of self-report. The small 
sample size also prevented us from detecting statistically 
significant differences between the groups, allowing us 
only to describe variables, which is in line with this the 
limitations inherent in a feasibility study. Despite these 
limitations, depressive symptoms measured by BDI scores 
decreased for most of the subjects, but these preliminary 
findings must also be interpreted with caution.
Descriptive results from the gambling diary show that 
gambling behaviour is fluctuating in nature, even though 
use of study medication tended to decline in both groups 
during the 8-week treatment period and group A reported 
an increase in gambling expenditure from pretreat-
ment to post-treatment. Achieving sustained changes in 
behaviour and adherence to study medication may require 
more psychosocial support and follow-up, and a longer 
duration of intervention. Changes in gambling behaviour 
may be sustained with more structured, but nonetheless 
minimal psychosocial support, for example, increasing 
participants’ awareness of gambling and triggers for 
gambling, for example, by adding The Gambling Absti-
nence Self-efficacy Scale43 as a therapeutic tool along with 
a self-help booklet.37 38 Further, better assessment tools for 
gambling urge and severity of gambling44–46 would give a 
more accurate picture of gambling behaviour and enable 
us to better measure treatment efficacy.
What is next?
A randomised, placebo-controlled clinical trial ( Clinical-
Trials. gov: NCT03430180: https:// clinicaltrials. gov/; and 
EudraCT 2017-001946-93) in which we have increased 
psychologist appointments, provided a self-help booklet, 
regularly review the gambling diary and adherence to 
study medication, and will give participants feedback 
every 3 weeks. The naloxone nasal spray will be used 
in the same as needed manner, and the primary objec-
tive is to investigate the efficacy of naloxone in adults 
with GD. The secondary objectives are to determine 
the effects of intranasal naloxone on gambling severity, 
gambling expenditure, gambling frequency and duration 
of gambling. The safety of intranasal naloxone will also 
be monitored. The duration of the upcoming trial is 12 
weeks, with three clinic visits (baseline and weeks 6 and 
12) and two supportive phone calls (weeks 3 and 9).37 38 
Because there are no medications approved to treat GD, 
behavioural interventions are viewed as Standard of Care 
(SOC). In order for naloxone to be viewed as effective 
in treating GD, it must produce a clinically meaningful 
effect on gambling behaviours over and above SOC.
ConClusIons
The acceptability and feasibility of using the naloxone 
nasal spray were high in this pilot study. AEs were 
consistent with those reported after oral and parenteral 
administration of opioid antagonists. This small, open-
label study reflects a general tendency across groups for 
gambling behaviour to reduce. The study resulted in 
several concepts that were employed to develop the study 
protocol for the next phase, a larger, randomised, place-
bo-controlled trial. These results, together with a growing 
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body of evidence for the pivotal role of the brain’s opioid 
systems in addictions,47–49 highlight the need to further 
investigate the utility of intranasal naloxone in the treat-
ment of GD.
Patient and public involvement
This research was done without patient involvement. 
Patients were not invited to comment on the study 
design and were not consulted to develop patient rele-
vant outcomes or interpret the results. Patients were not 
invited to contribute to the writing or editing of this docu-
ment for readability or accuracy. Patients were informed 
about the time of dissemination of the results.
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